Trending...
- Spokane: Council to Hold Press Conference to Discuss Further Information on Department of Justice Grant
- TBM Council Appoints U.S. Department of Transportation CDIO Pavan Pidugu to Board of Directors
- $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Power Business Solutions Announces Joint Venture with EIG Global Trust to Deliver Data Center Financial Solutions
- Scoop Social Co. Partners with Fairmont Hotels & Resorts to Elevate Summer Guest Experiences with Italian Inspired Gelato & Beverage Carts
- Spokane: Standoff With Domestic Violence Suspect Resolves Peacefully
- Velixo Unveils Velixo Intelligence, Its New AI-Powered Assistants, at Acumatica Summit
- GlobalBoost Media Advances Uncensorable Web on Blockchain with New Exchange Listings
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Top Law Firms In 2025 - Expert Law Attorneys
- Best Personal Injury Attorneys Of 2025 - ELA Awards
- Best Personal Injury Law Firms 2025 - ELA Awards
- Baruch Arcade Launches AI-Powered Gaming Platform on Solana, do I smell an airdrop?
- Arux Group Launches WA Security Training Programs
- Expert Law Attorneys 2025 Best Attorneys
- Best Family Law Attorneys Of 2025 - ELA Awards
- Best Criminal Defense Attorneys Of 2025 - ELA Awards
- Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
- Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
- New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
- GlobalBoost Media (BSTY) Shows Bullish Signals: Technical Analysis and Exchange Updates
- Spokane: Male In Custody After Puppy Is Thrown From Moving Vehicle During Argument; Puppy Located By Neighbor Unharmed
- $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
- The Brave and the Rescued Honors LA Fire Department First Responders
- Slick Cash Loan shares credit score tips for borrowers using bad credit loans
- Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
- PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude
- Spokane: Council to Hold Press Conference to Discuss Further Information on Department of Justice Grant
- UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token